Immunotherapy May Not Extend Breast Cancer Survival
For patients with advanced breast cancer, new trial data shows immunotherapy added to chemotherapy did not improve survival.
Updated on Oct. 25, 2026 in Cancer
The KEYNOTE-B49 trial found that adding the immunotherapy drug pembrolizumab to chemotherapy did not improve overall survival in patients with HR-positive, HER2-negative advanced breast cancer. While the study showed a progression-free survival benefit, the results suggest no long-term survival advantage for this patient population.
Why it matters
This development clarifies the limitations of immunotherapy in this specific subset of advanced breast cancer, highlighting the need for clinicians to carefully weigh treatment benefits against side effect risks. The trial also underscores the difficulty in enrolling patients with specific PD-L1-expressing tumors for clinical research.
The Phase 3 KEYNOTE-B49 trial measured outcomes in patients with PD-L1-expressing advanced breast cancer, finding a 26% reduction in progression-free survival but no improvement in overall survival compared to placebo. Due to reduced enrollment, the study reached only 65% statistical power.
The players
Pembrolizumab
An immunotherapy medication that targets the PD-1 pathway to assist the immune system in attacking tumor cells.
The details
Pembrolizumab works by blocking the PD-1 protein on immune cells, which in theory helps the immune system better recognize and fight cancer cells. However, in this trial, the combination with first-line chemotherapy showed higher rates of severe treatment-related adverse events, at 37.6% versus 32.7% for the placebo arm. Furthermore, treatment discontinuation due to these side effects was twice as high in the immunotherapy group compared to those receiving only chemotherapy.
Timeline
KEYNOTE-B49 trial results were presented at the ESMO Congress 2026.
Health Landscape
This finding arrives as researchers continue to test the boundaries of immunotherapy in breast cancer sub-types that have traditionally been less responsive to the treatment. It marks a shift in focus toward alternative drug combinations currently being explored in clinical research programs.
Patients with advanced breast cancer should discuss these trial results with their oncologist to understand how they influence current treatment standards. Those concerned about side effects should note that the trial showed higher rates of treatment discontinuation in the immunotherapy group.
The takeaway
The KEYNOTE-B49 trial indicates that adding pembrolizumab may not offer a survival benefit for patients with this specific breast cancer type. Patients should consult their care team regarding the most evidence-backed therapy options and monitor closely for any treatment-related side effects.
Further reading
For more information on the latest research in this field, visit our Cancer section.
